Mesalazine rectal 1g suppositories (MAX 002) - Aptalis Pharma

Drug Profile

Mesalazine rectal 1g suppositories (MAX 002) - Aptalis Pharma

Alternative Names: 5-ASA 1g rectal suppositories - Aptalis Pharma; MAX 002; MAX-002 1g suppositories - Aptalis Pharma; Mesalamine 1g rectal suppositories - Aptalis Pharma; Mesalazine rectal high-concentration - Aptalis Pharma

Latest Information Update: 07 May 2014

Price : $50

At a glance

  • Originator Axcan Pharma
  • Developer Aptalis
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ulcerative proctitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Canada (Rectal)
  • 07 May 2014 No development reported - Phase-III for Ulcerative proctitis in Poland (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top